Erasmus School of Health Policy & Management
External PhD candidate | Health Technology Assessment (HTA)
- pennings@eshpm.eur.nl
More information
Work
- Elise R.A. Pennings, Anne M. Spanjaart, Frederick W. Thielen, Simone Oerlemans, Anna Fleischer, Carmen Sanges, Maria Gomes Da Silva, Yolanda Cabrerizo, Pacôme Lecot, Lutgart Roux-Opstaele, Caroline Dreuillet, Eglys Gonzalez-Marcano, Olga Millán, Ulrich Jaeger, Julio Delgado, Maik Luu, Barbara Huber, Margot Lorrain, Mariana Pina, Andreas Kremer, Natacha Bolaños, Solène Clavreul, Samantha Nier, Roberto D.K. Liu, Birgit I. Lissenberg-Witte, Sébastien Anguille, Marie Robin, Emma C. Morris, Anna Sureda, Marie Préau, Myriam Pannard, Geertruida H. De Bock, Scott S. Wagers, Hélène Negre, Delphine Maucort-Boulch, Michael Hudecek, Carin A. Uyl-de Groot & Marie José Kersten (2025) - Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe - Blood Advances, 9 (24), 6380-6393 - doi: 10.1182/bloodadvances.2025017081 - [link]
- Janneke W. de Boer, Kylie Keijzer, , Suzanne van Dorp, Pim G.N.J. Mutsaers, Anne G.H. Niezink, Jaap A. van Doesum, Yasmina I.M. Serroukh, Louise W. Muntendam, Astrid E. Pulles, Esther J. Kret, Aniko Sijs-Szabo, Jesse Oomen, Astrid M.P. Demandt, Wendy B.C. Stevens, Maria T. Kuipers, Elise R.A. Pennings, Anne M. Spanjaart, Marie José Kersten, Margot Jak, Lisanne V. van Dijk, Marjolein W.M. van der Poel, Joost S.P. Vermaat & Tom van Meerten (2025) - Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R/R LBCL - Blood Advances, 9 (21), 5641-5650 - doi: 10.1182/bloodadvances.2025016689 - [link]
- Elise R.A. Pennings, Müjde Durmaz, Otto Visser, Eduardus F.M. Posthuma, Djamila E. Issa, Martine E.D. Chamuleau, Pieternella J. Lugtenburg, Marie José Kersten & Avinash G. Dinmohamed (2024) - Treatment and outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma: a contemporary, nationwide, population-based study in the Netherlands - Blood Cancer Journal, 14 (1) - doi: 10.1038/s41408-023-00970-z - [link]
- Janneke W. de Boer, Kylie Keijzer, Elise R.A. Pennings, Jaap A. van Doesum, Anne M. Spanjaart, Margot Jak, Pim G.N.J. Mutsaers, Suzanne van Dorp, Joost S.P. Vermaat, Marjolein W.M. van der Poel, Lisanne V. van Dijk, Marie José Kersten, Anne G.H. Niezink, Tom van Meerten & (2023) - Population-Based External Validation of the EASIX Scores to Predict CAR T-Cell-Related Toxicities - Cancers, 15 (22) - doi: 10.3390/cancers15225443 - [link]
- Janneke W. de Boer, Elise R.A. Pennings, Ankie Kleinjan, Jaap A. van Doesum, Anne M. Spanjaart, Pim G.N.J. Mutsaers, Margot Jak, Marjolein W.M. van der Poel, Maria T. Kuipers, Judit A. Adam, Arjan Diepstra, Lianne Koens, Suzanne van Dorp, Joost S.P. Vermaat, Anne G.H. Niezink, Marie José Kersten & Tom van Meerten (2023) - Inflammatory reactions mimic residual or recurrent lymphoma on [<sup>18</sup>F]FDG-PET/CT after CD19-directed CAR T-cell therapy - Blood Advances, 7 (21), 6710-6716 - doi: 10.1182/bloodadvances.2023010665 - [link]
- Anne M. Spanjaart, , Elise R.A. Pennings, Pim G.N.J. Mutsaers, Suzanne van Dorp, Margot Jak, Jaap A. van Doesum, Janneke W. de Boer, Anne G.H. Niezink, Milan Kos, Joost S.P. Vermaat, Aniko Sijs-Szabo, Marjolein W.M. van der Poel, Inger S. Nijhof, Maria T. Kuipers, Martine E.D. Chamuleau, Pieternella J. Lugtenburg, Jeanette K. Doorduijn, Yasmina I.M. Serroukh, Monique C. Minnema, Tom van Meerten & Marie José Kersten (2023) - The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands - Cancers, 15 (17) - doi: 10.3390/cancers15174334 - [link]
- Anne M. Spanjaart, Elise R.A. Pennings, Milan Kos, Pim G.N.J. Mutsaers, Pieternella J. Lugtenburg, Tom Van Meerten, Jaap A. Van Doesum, Monique C. Minnema, Margot Jak, Suzanne Van Dorp, Joost S.P. Vermaat, Marjolein W.M. Van Der Poel, Martijn G.H. Van Oijen, Maria T. Kuipers, Inger S. Nijhof & Marie José Kersten (2023) - Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities - JCO Oncology Practice, 19 (3), E407-E416 - doi: 10.1200/OP.22.00501 - [link]
